1
Return

Orelabrutinib for systemic lupus erythematosus: A randomised, double-blind, placebo-controlled study

delete2026-05-29
delete0
PRE
AI
R
Ru Li
X
Xue Li
X
Xiaoxia Zhu
S
Shengyun Liu
X
Xiao Zhang
C
Changhao Xie
Z
Zili Fu
A
Anbin Huang
L
Lingyun Sun
D
Dongzhou Liu
J
Jinxia Zhao
L
Ling Wu
Z
Zhanguo Li *
DOI：10.1016/j.jaut.2026.103578delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
• Orelabrutinib was safe and well tolerated. • Orelabrutinib suggested potential dose-dependent efficacy in active SLE. • Greater efficacy signals were observed in higher-activity patients. • Orelabrutinib showed high BTK occupancy and low off-target effects.

Journal

Journal of Autoimmunity cover
Journal of Autoimmunity
IF:
7
Papers:
3.1K
Citations:
1.0W

Organization

U
university of hong kong
Scholars:
3.0K
Papers: 1.4K
Citations: 0
Z
zhengzhou university
Scholars:
9.4K
Papers: 2.7K
Citations: 2
F
fudan university
Scholars:
11.3W
Papers: 7.6W
Citations: 121
B
Bengbu Medical College
Scholars:
62
Papers: 31
Citations: 2.2K
N
nanjing drum tower hospital
Scholars:
218
Papers: 74
Citations: 0
P
peking university
Scholars:
11.5W
Papers: 8.6W
Citations: 146
S
ShenZhen People's Hospital
Scholars:
74
Papers: 38
Citations: 940
S
shanxi medical university
Scholars:
1.7W
Papers: 7.9K
Citations: 114
G
Guangdong Provincial People's Hospital
Scholars:
525
Papers: 137
Citations: 7.3K
H
huazhong university of science and technology
Scholars:
2.3W
Papers: 7.2K
Citations: 5
Cited Papers

Cited Papers

Citing Papers

Citing Papers